Detalhe da pesquisa
1.
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
J Med Virol
; 90(11): 1739-1744, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29900553
2.
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Mov Disord
; 33(6): 928-936, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29570853
3.
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Lancet
; 385(9986): 2502-9, 2015 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25837829
4.
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Gastroenterology
; 149(4): 971-80.e1, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26170136
5.
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Mov Disord
; 31(4): 530-7, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26817533
6.
Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.
Antimicrob Agents Chemother
; 59(11): 6807-15, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26282418
7.
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Mov Disord
; 30(4): 500-9, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25545465
8.
Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.
Mov Disord Clin Pract
; 4(6): 829-837, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29242809
9.
Gulf War veterans' health: medical evaluation of a U.S. cohort.
Ann Intern Med
; 142(11): 881-90, 2005 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-15941694
10.
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Lancet Gastroenterol Hepatol
; 1(1): 36-44, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28404110
11.
Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
J Parkinsons Dis
; 5(1): 165-74, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25588353
12.
A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.
J Alzheimers Dis
; 42(3): 959-71, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25024314
13.
Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.
J Am Acad Child Adolesc Psychiatry
; 50(1): 73-84.e1, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21156272